A novel series of 2-(3-indolyl)alkylamino-1-(3-chlorophenyl)ethanols was prepared and evaluated for in vitro ability to stimulate cAMP production in Chinese hamster ovary cells expressing cloned human beta(3)-AR. The optically active 30a was found to be the most potent and selective human beta(3)-AR agonist in this series with an EC(50) value of 0.062nM. In addition, 30a selectivity for human beta(3)-AR
Discovery of a Novel and Potent Human and Rat .BETA.3-Adrenergic Receptor Agonist, [3-[(2R)-[[(2R)-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]acetic Acid
side (RHS, benzene ring) in the 'first generation' beta3-AR agonists BRL 37344 and CL 316243 with a 1H-indole ring gave compound 31 with unique pharmacological properties among beta3-AR agonists. Initial in vitro assays showed that 31 possesses modest rat and human beta3-ARs agonistic activity. Introduction of various substituent into the indole nucleus of 31 afforded a number of compounds with good beta3-ARs
Design and synthesis of Osthole-based compounds as potential Nrf2 agonists
作者:Weiwei Huang、Yi Huang、Jiayan Cui、Yuhang Wu、Fuli Zhu、Jin Huang、Lei Ma
DOI:10.1016/j.bmcl.2022.128547
日期:2022.4
A total of 23 compounds based on Osthole skeleton were designed and synthesized. Their agonistic activity for Nrf2 were evaluated by Dual-luciferase Reporter Gene Assay. Most of the compounds showed better activities compared with Osthole, especially O15 and O21. And the median effective concerntration (EC50) values was calculated accordingly, both of which showed remarkable activity for Nrf2. The
Selective estrogen receptor degraders and uses thereof
申请人:INVENTISBIO INC.
公开号:US10647724B2
公开(公告)日:2020-05-12
The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
本公开提供了式 (I) 和式 (II) 的化合物。本文所述化合物可用于治疗增殖性疾病(如癌症)。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。
Velluz, Annales Pharmaceutiques Francaises, 1959, vol. 17, p. 15,21